ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGRX Agile Therapeutics Inc

0.6022
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agile Therapeutics Inc NASDAQ:AGRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.6022 0.27 0.2994 0 01:00:00

Amended Statement of Beneficial Ownership (3/a)

23/11/2020 9:46pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Conway Robert G
2. Date of Event Requiring Statement (MM/DD/YYYY)
10/3/2017 

3. Issuer Name and Ticker or Trading Symbol

AGILE THERAPEUTICS INC [AGRX]
(Last)        (First)        (Middle)

101 POOR FARM ROAD
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
SVP Chief Supply Chain Officer /
(Street)

PRINCETON, NJ 08540      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
10/12/2017 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 6200 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) These shares were inadvertently omitted from the Reporting Person's original Form 3, and also were inadvertently omitted from subsequent Forms 4 filed by the Reporting Person after his original Form 3 was filed.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Conway Robert G
101 POOR FARM ROAD
PRINCETON, NJ 08540


SVP Chief Supply Chain Officer

Signatures
/s/ Robert G. Conway11/23/2020
**Signature of Reporting PersonDate

1 Year Agile Therapeutics Chart

1 Year Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

Your Recent History

Delayed Upgrade Clock